
-
British cycling icon Hoy and wife provide solace for each other's ills
-
Money, power, violence in high-stakes Philippine elections
-
Iran, US hold second round of high-stakes nuclear talks in Rome
-
Japanese warships dock at Cambodia's Chinese-renovated naval base
-
US Supreme Court pauses deportation of Venezuelans from Texas
-
Pakistan foreign minister arrives in Kabul as Afghan deportations rise
-
Heat and Grizzlies take final spots in the NBA playoffs
-
Iran, US to hold second round of high-stakes nuclear talks in Rome
-
Humanoid robots stride into the future with world's first half-marathon
-
Migrant's expulsion puts Washington Salvadorans on edge
-
Plan for expanded Muslim community triggers hope, fear in Texas
-
Pakistan foreign minister due in Kabul as deportations rise
-
White House touts Covid-19 'lab leak' theory on revamped site
-
Dodgers star Ohtani skips trip to Texas to await birth of first child
-
SFWJ / Medcana Announces Strategic Expansion Into Australia With Acquisition of Cannabis Import and Distribution Licenses
-
US senator says El Salvador staged 'margarita' photo op
-
Ford 'adjusts' some exports to China due to tariffs
-
Thomas maintains two-shot lead at RBC Heritage
-
US to withdraw some 1,000 troops from Syria
-
Four killed after spring storms wreak havoc in the Alps
-
Spurs' Popovich reportedly home and well after 'medical incident'
-
Trump goes to war with the Fed
-
Celtics chase second straight NBA title in playoff field led by Thunder, Cavs
-
White House site blames China for Covid-19 'lab leak'
-
Norris edges Piastri as McLaren top Jeddah practice
-
Trump warns US could ditch Ukraine talks if no progress
-
Judge denies Sean 'Diddy' Combs push to delay trial
-
80 killed in deadliest US attack on Yemen, Huthis say
-
Lebanon says two killed in Israeli strikes in south
-
Trump says US will soon 'take a pass' if no Ukraine deal
-
F1 success is 'like cooking' - Ferrari head chef Vasseur
-
Cycling mulls slowing bikes to make road racing safer
-
Macron invites foreign researchers to 'choose France'
-
Klopp 'happy' in new job despite Real Madrid rumours: agent
-
Alcaraz into Barcelona semis as defending champion Ruud exits
-
Vance meets Italy's Meloni before Easter at the Vatican
-
Evenepoel returns with victory in Brabantse Pijl
-
Maresca confident he will survive Chelsea slump
-
Mob beats to death man from persecuted Pakistan minority
-
Lebanon says one killed in Israeli strike near Sidon
-
Arsenal's Havertz could return for Champions League final
-
US officials split on Ukraine truce prospects
-
Client brain-dead after Paris cryotherapy session goes wrong
-
Flick demands answers from La Liga for 'joke' schedule
-
'Maddest game' sums up Man Utd career for Maguire
-
Trial opens for students, journalists over Istanbul protests
-
Gaza rescuers say Israeli strikes kill 24 after Hamas rejects truce proposal
-
'Really stuck': Ukraine's EU accession drive stumbles
-
'Not the time to discuss future', says Alonso amid Real Madrid links
-
74 killed in deadliest US attack on Yemen, Huthis say

ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025
ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced its participation in the upcoming iFX EXPO Dubai.
ALT5 will be exhibiting through the three days of the show at the Dubai World Trade Centre, providing product demonstrations, solutions and general information to many of the 7,000+ attendees starting January 14th in booth #26.
iFX EXPO Dubai 2025 is the ultimate meeting place for brokers, affiliates, traders, investors, and tech- and service-providers who are looking to succeed in the MENA region.
"ALT5 continues to showcase at iFX tradeshows around the world because it is a very significant and important industry segment. By listening to and engaging with new and existing clients at iFX Dubai, ALT5 remains on the leading edge of innovation and technology. We finished 2024 with strong business momentum and look to continue that into the new year." said Vay Tham, CRO ALT5 Sigma Corporation.
About ALT5 Sigma
The Company is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.
Launched in 2018, ALT5 Sigma Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime". ALT5 Sigma Inc. processed over US$1.2 billion in cryptocurrency transactions in 2023.
ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.
Through its biotech activities, the Company is developing innovative, actionable solutions intended to help end the opioid crisis. The Company is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also contains statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.
Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Contact Information
Investor Relations
[email protected]
1-800-400-2247
SOURCE: ALT5 Sigma Corp
F.Pedersen--AMWN